Mounjaro Lawsuit – January 2025 Update
Mounjaro Lawsuit Overview
People are filing Mounjaro lawsuits after experiencing a range of severe side effects from taking the the GLP-1 drug. Mounjaro is the brand name for a drug called tirzepatide, manufactured by pharmaceutical giant Eli Lilly and Company. The drug is used for glycemic control in Type 2 diabetes, but clinical trials showed significant weight loss benefits for people with an elevated body mass index (BMI). It is widely considered a successor to Ozempic, which took the market by storm.
Almost immediately, there were reports of severe side effects, including gastroparesis and gastroenteritis. Despite the reported adverse events, there have been no recalls issued for the drug. Lawsuits now allege that the manufacturer of Mounjaro knew the potential for severe side effects and failed to warn consumers.
Our firm is currently investigating Mounjaro lawsuits involving a diagnosis of:
- Gastroparesis
- Gastrointestinal obstruction/ileus
- Daily vomiting lasting at least 3 weeks
- Blindness (NAION)/vision problems
- Blood clots/deep vein thrombosis (DVT) or pulmonary embolism (PE)
Individuals who have suffered adverse health conditions after using Mounjaro are strongly encouraged to contact King Law to schedule a free, no-obligation consultation.
Mounjaro Lawsuit – 2025 Update
December 2, 2024: Number of Mounjaro and GLP-1 Lawsuits Grows to 1,300 in December
As of December 2, 2024, 1,300 people have alleged injuries from Mounjaro and other GLP-1 drugs and filed lawsuits as part of multidistrict litigation. Mounjaro’s manufacturer Eli Lilly and Company is a defendant in some of these lawsuits. The patients filing these lawsuits allege that after taking Mounjaro for their type 2 diabetes they experienced severe side effects including, blood clots, vision loss, and gastrointestinal conditions. It is expected more people will file lawsuits against Eli Lilly and other GLP-1 manufacturers.
November 22, 2024: Researchers Say More Studies Should Examine GLP-1 Drugs, Like Mounjaro, And Cancer Risks
A recent French study published in Endocrine Connections looked into data from patients who used GLP-1 drugs, like Mounjaro, for 1 to 3 years. The researchers found those people were 58% more likely to develop cancers of the thyroid. The study, called “Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?” called for more research into GLP-1 drugs and how they may be carcinogenic to humans.
November 1, 2024: FDA Issues Letter Warning People About Compounded GLP-1 Drugs
As more pharmacies compound GLP-1 drugs for weight loss, the FDA issued a warning to patients who take these versions of GLP-1 drugs. The FDA said that they have received 136 reports of adverse events occurring in people using compounded GLP-1 drugs containing tirzepatide for weight loss. Tirzepatide is the active ingredient in Mounjaro. In the warning, the FDA reminded consumers that compounded drugs are not evaluated by the FDA for safety, effectiveness, and quality.
October 9, 2024: FDA Announces End of Terzepatide Shortage; More Mounjaro Lawsuits Likely
On October 2, 2024, the U.S. FDA determined the end of the tirzepatide shortage occurring since 2022. In their statement, the FDA said they have confirmed with the drug’s manufacturer (Eli Lilly and Company) that, “their stated product availability and manufacturing capacity can meet the present and projected national demand.”
Tirzepatide is the active ingredient in the GLP-1 drug Mounjaro. As the supply of Mounjaro increases to meet growing demand, more people are likely to experience the severe side effects associated with the drug. That means Eli Lilly will likely face more lawsuits from people who were harmed by Mounjaro.
October 4, 2024 – Sharp Rise in Lawsuits Against Eli Lilly and other GLP-1 Manufacturers
The number of lawsuits against manufacturers of GLP-1 drugs, such as Eli Lilly’s Mounjaro, saw a 20% rise in September. By October 1, 2024, 1,090 cases had been filed in MDL 3092, many involving claims against the Mounjaro manufacturer. This surge in legal actions is linked to an increasing number of Americans experiencing serious side effects after using GLP-1 agonist drugs. We expect the wave of lawsuits to continue, with tens of thousands more possible cases in the coming months.
October 4, 2024 – Plaintiffs’ Lawyers Say Eli Lilly Is Trying to Change the Terms of the GLP-1 Lawsuit Proceedings
Lawyers for the Plaintiffs in the GLP-1 lawsuit say that a defendant (Eli Lilly, maker of Mounjaro) is trying to violate their rights. In a letter to the Judge, Plaintiffs’ lawyers expressed dismay that Eli Lilly requested Plaintiff Fact Sheets sooner than 90 days. Their biggest objection was that the protocol was previously decided and Eli Lilly now wants to change the terms of the negotiated agreement. This agreement was memorialized in case management order number 12. Plaintiff fact sheets give defendants basic information about the individuals who file a lawsuit.
September 24, 2024 – Alabama Woman Files Mounjaro Lawsuit Against Eli Lilly for Severe Gastrointestinal Injuries
A 46-year-old woman from Alabama has filed a complaint in the Mounjaro lawsuit against the defendant, Eli Lilly. She used the drug from August 2022 until April 2023 and claims to have suffered from gastrointestinal injuries. The plaintiff alleges that if her prescribing doctor had been informed of the severe side effects, such as gastroparesis or cyclical vomiting, she would not have taken the medication. Gastroparesis is a condition that paralyzes the stomach, preventing proper digestion and emptying. There is currently no known cure for gastroparesis, and symptoms can only be managed. Eli Lilly is accused of not adequately testing Mounjaro for safety risks.
September 10, 2024 – Mounjaro Drugmaker to Sell Tirzepatide D2C Through Its Online Pharmacy
Eli Lilly, the manufacturer of Mounjaro, recently announced plans to begin selling low doses of tirzepatide, the active ingredient in Mounjaro and Zepbound, directly to consumers. As the demand for purchasing medications from online telehealth providers continues to grow, Eli Lilly is the first GLP-1 drugmaker to take this step, citing a commitment to protecting customers from compounded versions of GLP-1 medications.
August 8, 2024 – Judge Marston Issues Discovery Order in Mounjaro Lawsuit
Judge Marston has issued a 19-page order outlining how discovery will proceed in the Mounjaro Lawsuit. The first major step in MDL 3094 is the request for and production of millions of pages of documents by Mounjaro manufacturer Eli Lilly. The judge has ordered the lawyers to meet and discuss who they believe will have relevant information. The judge has indicated that electronic data must be maintained, and all versions of emails should be produced. The order also notes that the parties should discuss how text messages, internal chats, or social media platforms might have been used to maintain communications or discoverable material. The parties will typically have many disagreements about what should be produced. Plaintiffs want more information; defendants want to produce less. This is a critical development in any major federal lawsuit and will likely take over a year to complete.
August 2, 2024 – Blood Clots, DVT, Pulmonary Embolisms Linked to GLP-1 Drugs
A data analysis published in the Endocrine Journal has medical professionals taking a new look at how semaglutide drugs might cause a specific type of blood clot. The type of clot, called a deep vein thrombosis (DVT), can cause pulmonary embolisms and death or lung damage.
The data analysis looked at trial outcomes for people taking semaglutide drugs to manage their type 2 diabetes. Data from that analysis found a 266% increase in the risk of DVT for people taking semaglutide drugs.
Mounjaro belongs to the same class of drugs as semaglutide drugs. The active ingredient in Zepbound is tirzepatide, which is a GLP-1 (glucagon-like peptide-1) agonist. More research will be conducted to see if all GLP-1 drugs carry a similar risk of blood clots and DVT.
August 1, 2024 – Mounjaro Lawsuit Progresses with Bellwether Trials Set for Late 2025
Proceedings are moving forward in preparations for the bellwether trials set to start at the end of 2025. Attorneys representing the plaintiffs in the Mounjaro lawsuit have submitted their Notice of Appearance, called pro hac vice. This motion allows lawyers to practice law outside of their licensed jurisdiction. The attorney must file an affidavit to show they are in good standing with their State Bar and have read the most recent edition of the local court’s Rules of Professional Conduct.
July 30, 2024 – Study Links Active Ingredient in Some GLP-1 Drugs to Vision Loss
A new study published in the Journal of the American Medical Association’s Ophthalmology linked semaglutide drugs to a type of eye strokes called nonarteritic anterior ischemic optic neuropathy (NAION). Semaglutide drugs may cause eye strokes that cause permanent vision loss. This warning was not included in the initial drug-warning labels of many semaglutide drugs.
Drugs like Ozempic, Wegovy, and Rybelsus belong to a class of drugs called GLP-1 (Glucagon-like peptide-1) receptor agonists. The active ingredient in Zepbound, tirzepatide, belongs to this same class of drugs. There is a possibility that future studies will find a link between vision loss and other GLP-1 drugs, such as Zepbound.
June 17, 2024 – Mounjaro Lawsuit Advances with First Status Conference Under New Judge Karen Marston
On June 10, 2024, the new judge in the Mounjaro lawsuit, Karen Marston, held the first status conference since Judge Pratter’s passing. The primary focus of the status conference was on the logistics of moving MDL 3094 forward. Since the conference, Judge Marston has already issued two new orders. The first allows attorneys who wish to file cases into the GLP-1 MDL to do so without paying a fee to be admitted pro hac vice. The second order, issued with the judge’s permission, concerns a motion filed by the parties specific to privilege logs. In lawsuits, parties are required to turn over relevant information to the other side, but sometimes privileges can be asserted. If a document is not turned over due to privilege, then it must be logged, and the other side informed that it exists.
June 9, 2024 – Judge Karen Spence Marston to Preside Over Mounjaro Lawsuit
Case management order number 7 has informed the parties of a new presiding judge in the Mounjaro lawsuit. Judge Karen Spence Marston will now oversee the proceedings. We anticipate the Ozempic lawsuit to be substantial, involving numerous intricate legal motions. Judge Marston, a distinguished graduate of Wake Forest Law School, will undoubtedly face significant challenges in this case. Her legal acumen will be put to the test. The Judge has already acted promptly, scheduling an in-person conference for June 10, 2024.
May 20, 2024 – Judge Change in Mounjaro Lawsuit Following Judge Pratter’s Death
The Mounjaro lawsuit is affected by the death of Judge Gene Pratter, who was considered a conservative judge. The Judicial Panel on Multidistrict litigation will appoint a new judge to the Mounjaro lawsuit in the near future. The change in judge will likely delay some upcoming court conferences. There was also rumor that early rulings in the MDL would lead to a large state court docket in New Jersey. This is a major development for Mounjaro cases and a hit for defendant Eli Lilly.
May 2, 2024 – Mounjaro Lawsuit “Science Day” Scheduled for June 14, 2024
The Mounjaro lawsuit is headed for a critical date on June 14, 2024. Judge Pratter has ordered the parties to appear for “Science Day” on that date. Case Management Order number five set the preliminary rules for Science Day. The plaintiffs will be allotted two and a half hours to discuss the background of how Mounjaro works and the common injuries associated with it. The Mounjaro cases are only part of the GLP-1 RAs product liability litigation. Another part of the lawsuit is focused on similar injuries caused by semaglutide drugs like Ozempic, Wegovy, and Rybelsus.
April 25, 2024 – Mounjaro Lawsuit Initiated with Plaintiffs’ First Statement of the Case
On April 9, 2024, Plaintiffs filed their first statement of the case in the Mounjaro Lawsuit. The Plaintiffs stated that tirzepatide is sold by Eli Lilly under the names Mounjaro and Zepbound. The plaintiffs’ allegation is very simple—that Eli Lilly did not warn of the risk of gastroparesis, ileus, or intestinal obstruction. The statement of the case highlights cases like Meredith Hotchkiss, who used Mounjaro and was later diagnosed with gastroparesis, a serious bowel injury. Plaintiffs also allege that users may need to use the drugs forever and that a large percentage of weight loss would be muscle.
April 20, 2024: Mounjaro Lawsuits Still in Early Stages
To date, the lawsuits against the maker of Mounjaro are still in the early stages of litigation. No settlements or trials are scheduled yet. However, litigation is expected to grow significantly due to life-altering side effects.
February 29, 2024: Mounjaro Lawsuits Consolidated into Multidistrict Litigation in Pennsylvania
With the number of lawsuits against the manufacturer of Mounjaro increasing, federal cases are consolidated into multidistrict litigation (MDL). Pre-trial proceedings will be heard in the Eastern District of Pennsylvania.
November 30, 2023: FDA Approves Zepbound for Chronic Weight Management in Adults
The FDA approves Zepbound as a treatment for chronic weight management in adults with obesity. Zepbound has the same active ingredient as Mounjaro, tirzepatide, and is manufactured by Eli Lilly.
August 28, 2023: Lawsuit Filed Against Makers of Mounjaro and Ozempic Over Side Effects Warning
CNN reports that a lawsuit has been filed against the makers of Mounjaro and Ozempic, alleging that they failed to warn consumers about the potential for severe side effects when using their drugs.
May 26, 2022: Mounjaro Approved for Treatment of Type 2 Diabetes in Adults
The U.S. Food and Drug Administration (FDA) approves Eli Lilly’s Mounjaro™ (tirzepatide) for treatment in adults with Type 2 diabetes.
On this page:
What Is Mounjaro and How Does It Work?
Mounjaro vs. Ozempic: The Similarities and Differences
Mounjaro Side Effects and Symptoms
Long-Term Side Effects of Mounjaro
Mounjaro Usage Linked to Stomach Paralysis
Mounjaro Manufacturer: Eli Lilly and Company
Mounjaro FDA-Approval and Its Black Box Warning
Mounjaro Active and Inactive Ingredients
Eligibility Criteria for Filing a Mounjaro Lawsuit
Statute of Limitations for a Mounjaro Lawsuit
How to File a Mounjaro Lawsuit
What Is Mounjaro and How Does It Work?
Mounjaro is a weekly injectable approved for the treatment of Type 2 diabetes in adults. It is the brand-name medication for tirzepatide, manufactured by Eli Lilly and Company. Mounjaro’s active ingredient works as a dual agonist for the GLP-1 (glucagon-like peptide-1) receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. This dual-action quality makes it unique to its predecessors. There is no generic version of the drug available on the market.
The drug was initially approved by the U.S. Food and Drug Administration on May 13, 2022, to manage blood sugar in adults with Type 2 diabetes. It is often prescribed alongside the recommendation for exercise and a balanced diet. The medication works by increasing insulin release and reducing sugar production in the liver. Ultimately, this process slows food emptying from the stomach, enhancing satiety. It is not approved for the treatment of Type 1 diabetes and is not to be started by individuals with current or past pancreatitis.
In November 2023, a version of the drug was approved for chronic weight management in adults with obesity or who are overweight with at least one weight-related condition. The drug is reportedly effective for weight loss because it mimics hormones that regulate appetite and blood sugar (GLP-1 and GIP). The suppression of appetite and alteration of stomach emptying weights has led to significant weight loss for some patients.
Mounjaro vs. Ozempic: The Similarities and Differences
While Mounjaro and Ozempic treat the same conditions, the underlying drug and their mechanisms are substantially different. Both drugs are FDA-approved for management of Type 2 diabetes. Ozempic, however, is also approved for reducing cardiovascular risks in people with Type 2 diabetes who have established cardiovascular disease.
Mounjaro is known for being more expensive than its counterpart; however, studies show that it is more effective in controlling blood sugar and aiding in weight loss. The drug’s mechanism of action is also unique. The active ingredient in Ozempic is semaglutide, a GLP-1 receptor agonist. The underlying drug in Mounjaro is a dual GIP and GLP-1 receptor agonist known as tirzepatide. It is the first of its kind on the market.
Both drugs are administered in weekly subcutaneous injections. The dosages differ substantially. Ozempic is available in 0.5 mg, 1 mg, and 2 mg dosages, while Mounjaro is available in 2 mg, 12.5 mg, and 15 mg dosages. Each drug may be prescribed off-label for weight loss and is effective in controlling blood sugar levels in patients with Type 2 diabetes. Unfortunately, both have also been linked to severe side effects. In some instances, Mounjaro may have additional side effects because of its dual-action mechanism.
Mounjaro Side Effects and Symptoms
The side effects of Mounjaro range from mild to severe, with some lasting long-term. One of the most concerning reported events after taking Mounjaro is serious gastrointestinal issues such as gastroparesis. These issues are commonly reported by individuals who were prescribed the drug for off-label obesity treatment.
Mounjaro side effects and symptoms:
- Gastroparesis (stomach paralysis)
- Ileus or intestinal blockage
- Disruption of normal digestion
- Gastroenteritis
- Cramps
- Diarrhea
- Severe or excessive vomiting
- Severe dehydration
- Pancreatitis
- Renal (kidney) complications
- Abdominal pain
- Gallbladder issues
- Delayed gastric emptying
- Acute kidney injury
- Risk of thyroid cancer
- Abdominal swelling
- Severe allergic reaction
Lawsuits that have been filed against Eli Lilly, the manufacturer of Mounjaro, allege that the maker did not provide adequate warnings about the potential for serious gastrointestinal effects after using the drug.
Long-Term Side Effects of Mounjaro
Long-term side effects of Mounjaro may include serious conditions such as prolonged vomiting and severe digestive issues such as stomach paralysis. Individuals with these conditions are strongly encouraged to seek legal counsel as soon as possible.
Potential long-term side effects of Mounjaro may include:
- Prolonged vomiting (Patient reports indicate it may last for weeks)
- Severe digestive issues
- Stomach paralysis (gastroparesis)
- Pancreatitis
Seeking prompt medical attention for any side effects you experience can help ensure you receive the care and treatment you need. It is essential to retain any medical records related to your condition. Evidence often plays a critical role in Mounjaro-related lawsuits.
Moujaro and Vision Loss
Some GLP-1 agonist drugs have been tied to vision loss and blindness. A study published in JAMA’s Ophthalmology found that people who took semaglutide drugs like Ozempic and Wegovy had an increased risk of NAION. This condition cuts off blood supply to the eye and can cause vision loss and blindness.
Mounjaro is a tirzepatide, but it belongs to the same class of drugs as semaglutide drugs. More studies and information will need to be gathered to see if Mounjaro could increase the risk of vision loss because of NAION.
Mounjaro and Blood Clots
Mounjaro belongs to a class of drugs called GLP-1 agonists. A study published in the Endocrine Journal showed some GLP-1 drugs (semaglutides) have been linked to an increased risk of developing blood clots. These blood clots are called deep vein thrombosis (DVT), and they can lead to pulmonary embolisms (PEs). These lung embolisms can lead to organ damage or death.
Mounjaro’s active ingredient is tirzepatide, which is also a GLP-1 drug. However, more research is needed to determine if tirzepatide drugs also increase the risk of DVT and PEs.
Mounjaro Usage Linked to Stomach Paralysis
One of the most concerning reported side effects of Mounjaro usage is its link to stomach paralysis or gastroparesis. Gastroparesis is a condition where the movement of the stomach muscles is disrupted. The disruption affects how food is propelled through the digestive system, which leads to slowed or halted stomach emptying. Patients with Type 2 diabetes have an increased risk of gastroparesis because of the potential for vagus nerve damage.
Recent studies highlight the increased risk for gastrointestinal issues when taking a GLP-1 receptor agonist like Mounjaro. Higher doses correlate with a more significant risk of nausea, vomiting, and gastroparesis. Because Mounjaro is prescribed at a higher dose compared to similar treatments, these side effects may be more severe.
Research also suggests a link between GLP-1 medications and adverse psychiatric events, although more studies are needed to detail the connection. Allegations against the manufacturer of Mounjaro include that the company failed to warn individuals about the risk of severe side effects, specifically for those predisposed to gastroparesis.
Mounjaro Manufacturer: Eli Lilly and Company
In early 2016, Mounjaro manufacturer Eli Lilly and Company applied for a patent for tirzepatide. The patent was published later that year. The pharmaceutical company then applied for FDA approval with a priority review voucher in October 2021 and received approval for the drug on May 13, 2022, for the treatment of Type 2 diabetes in adults.
The medication’s international nonproprietary name (INN) is Tirzepatide; however, it is sold under the brand names Mounjaro and Zepbound. In November 2023, the FDA approved Zepbound for weight management in adults with obesity.
Within a year of approval, the FDA began receiving reports of adverse health events from patients using the drug. These reports have also resulted in legal actions against the manufacturer. Allegations include that Eli Lilly failed to adequately warn users about the risk of adverse medical events, specifically gastroparesis. These allegations have led to questions about the drug’s safety and efficacy.
Mounjaro FDA-Approval and Its Black Box Warning
After applying for a patent for the drug tirzepatide in early 2016 and receiving publication later that year, Eli Lilly applied for approval with a priority review voucher in October 2021. The company received FDA approval for Mounjaro to treat Type 2 diabetes in adults in May 2022 following a priority review. On November 8, 2023, the FDA approved Zepbound for use in adults with obesity or those who are overweight with at least one weight-related condition.
The black box warning notes that GLP-1s such as Mounjaro are contraindicated for individuals with a history or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Mounjaro Active and Inactive Ingredients
Mounjaro is a weekly injectable and the active ingredient is tirzepatide. It is available in a pack containing four single-dose prefilled pens or in individual single-dose vials with a cardboard outer carton.
Inactive ingredients in Mounjaro:
- Sodium chloride
- Sodium phosphate dibasic heptahydrate
- Water for injection
The inactive ingredients are generally used for stabilization and pH adjustment. The pH may be adjusted with a hydrochloric acid solution and/or sodium hydroxide solution.
Eligibility Criteria for Filing a Mounjaro Lawsuit
In order to file a Mounjaro lawsuit, you must meet certain eligibility requirements. The best way to determine whether you meet the necessary criteria for filing a claim is by consulting with an experienced attorney.
Eligibility criteria for filing a claim:
- Proof of use of Mounjaro.
- Proof of adverse health condition (prolonged or persistent vomiting, gastroparesis, ileus, gastroenteritis, nausea, bile duct cancer, Lou Gehrig’s Disease (ALS), gallbladder cancer, sinus cancer, or diarrhea).
It is important to note that not all individuals who suffered a side effect after using Mounjaro will qualify for a lawsuit. An attorney can review your case to help determine whether you qualify during a consultation. If you qualify, you may be able to seek compensation for damages, including your medical expenses and lost wages.
Evidence to Collect for a Mounjaro Lawsuit:
In order to prove your claim, you may need to provide evidence. Working with an attorney can help ensure you collect the evidence you need to strengthen your case.
Evidence that may substantiate your claim:
- Medical records
- Prescriptions
- Emergency room visits
- Doctor’s notes
Statute of Limitations for a Mounjaro Lawsuit
The statute of limitations for a Mounjaro lawsuit can vary by state law. It is imperative to consult with an attorney as early in the process as possible to ensure you meet all legal requirements, including the statute of limitations. There may be several factors that can influence or extend the amount of time you have to file a claim including the state where the case is filed and the specifics of your diagnosis.
How to File a Mounjaro Lawsuit
There are multiple steps that you need to take to file a Mounjaro lawsuit. Working with an attorney can help you understand the process and ensure you receive the best possible outcome in the case.
Steps for filing a Mounjaro lawsuit:
- Initial consultation: As soon as possible, you should contact a lawyer for a free case review to determine your eligibility.
- Evidence gathering: Mounjaro lawsuits generally require evidence that supports the claim. Evidence may include medical records, testimonies, and documentation. Proof of damages is also essential which can be supported by evidence of your medical expenses, diagnosis, and purchase of Mounjaro.
- Filing the lawsuit: Your attorney and legal team will handle all paperwork related to your case and will make sure your claim is filed within the state-specific deadlines.
- Negotiation and court proceedings: Your attorney will work with the defendant(s) to negotiate a favorable settlement or set the matter for trial if a settlement cannot be reached.
Mounjaro Settlements and Payout Amounts
The anticipated settlement range for serious injuries in a Monjauro lawsuit is between $400,000 and $700,000; however, settlement values may vary depending on the case. There is no standardized settlement amount. The value of the settlement will depend on the individual damages in the case and may be based on factors like the extent of losses and injuries.
An experienced attorney can help maximize compensation. Without the help of an attorney, you may not be aware of the full range of damages or be able to secure the documentation necessary to prove your case.
Contact a Mounjaro Lawyer
Did you suffer gastroparesis or another adverse health condition after taking Mounjaro? You may be eligible for compensation. At King Law, we have extensive experience helping individuals who have had serious side effects after taking Mounjaro and other weight-loss drugs. Contact our office today to start the process of determining eligibility and filing a lawsuit against the makers of Mounjaro.
Frequently Asked Questions (FAQs)
Find answers to any major questions you have regarding eligibility in the Mounjaro lawsuits below.